Introduction {#sec1}
============

NPC disease is an inherited, autosomal recessive lysosomal storage disorder caused by loss-of-function mutations primarily in the *NPC1* gene (∼95%), leading to severe neurodegeneration and liver dysfunction ([@bib3; @bib24; @bib47; @bib48]). NPC1 is a transmembrane protein located on the late endosomal/lysosomal (LE/L) compartments where it regulates cholesterol efflux ([@bib1; @bib3; @bib24]). So far, more than 250 different *NPC1* mutations effecting protein expression, function and stability have been identified. The most common mutation associated with the classical juvenile-onset phenotype, *NPC1*^*I1061T*^, promotes ER-mediated degradation of the mutant protein ([@bib8]). Characteristic for NPC disease is the sequestration of low-density lipoprotein (LDL)-derived cholesterol and other lipids in the cellular LE/L compartments due to defective export ([@bib50]). Loss of NPC1 function causes impaired cholesterol homeostasis that has a major impact on liver and brain ([@bib47; @bib48; @bib50]).

Autophagy, an intracellular degradation pathway for damaged organelles and aggregation-prone proteins, is essential for cellular homeostasis ([@bib26; @bib32]). Autophagy regulates lipid metabolism and alterations in intracellular lipid content is likely to impact the autophagy pathway ([@bib40; @bib41]). The degenerative phenotypes in the liver and cerebellum observed in NPC patients resemble those seen in the organs of autophagy-deficient mice ([@bib12; @bib17; @bib18; @bib26; @bib33]), suggesting a role of autophagy in the etiology of NPC disease. The dynamic process of autophagy, defined as autophagic flux, encompasses the generation of autophagosomes and its fusion with late endosomes to form amphisomes, which subsequently fuse with lysosomes forming autolysosomes where the autophagic cargo is degraded ([@bib32]). Although impaired autophagy has been shown to contribute to neurodegenerative and liver disorders ([@bib16; @bib26; @bib36]) and is implicated in NPC disease ([@bib6; @bib28; @bib30; @bib38]), the exact nature of autophagy dysfunction in human NPC disease-affected cells has not been clarified.

The generation of NPC patient-specific induced pluripotent stem cells (iPSCs) provides access to unlimited numbers of disease-affected cell types and a unique opportunity to gain mechanistic insights and screening for new cell type-specific therapeutic compounds ([@bib10; @bib12; @bib19; @bib35; @bib43; @bib42; @bib51]). Isogenic iPSCs that differ exclusively in a single disease-causing genetic mutation enable studying of the disease phenotypes under highly controlled conditions and allow linking the observed defects directly to disease-causing genetic alterations ([@bib44]).

Here, we report the generation of patient-specific NPC1 iPSCs and isogenic mutant and control cell lines. NPC1 iPSC-derived hepatic and neuronal cells showed reduced cell viability compared to their controls and displayed defects in cholesterol metabolism and impairment in autophagic flux. TALEN-mediated correction of the *NPC1*^*I1061T*^ mutation rescued these disease phenotypes, including dysfunctional autophagic flux, thus implying that the defect in autophagy is directly linked to loss of NPC1 protein function. Screening of small molecule autophagy inducers identified compounds that could rescue the block in autophagy, leading to increased cell viability in NPC1-deficient hepatic and neuronal cells.

Results {#sec2}
=======

Generation and Characterization of NPC Patient-Specific iPSCs {#sec2.1}
-------------------------------------------------------------

We generated transgene-free iPSCs from fibroblasts of NPC patients ([Table 1](#tbl1){ref-type="table"}) using Cre-excisable lentiviruses ([Figure S1](#app3){ref-type="sec"}A available online) ([@bib43; @bib45]) and derived up to 15 independent NPC1 iPSC lines from each patient sample ([Table 1](#tbl1){ref-type="table"}). We chose those with the lowest number of viral integrations for Cre-recombinase-mediated vector excision, which was confirmed by Southern blot analysis ([Figures S1](#app3){ref-type="sec"}B and S1C). NPC1 iPSC lines expressed transcripts of endogenous pluripotency-related genes, stained positive for pluripotency markers, displayed a normal karyotype and were capable of forming teratomas with contribution to all three embryonic germ layers ([Figures S1](#app3){ref-type="sec"}D--S1G). NPC1 protein levels were markedly reduced in NPC1 iPS-derived cells compared to control cells ([Figure S1](#app3){ref-type="sec"}H). To generate disease-affected cell types, we induced hepatic ([@bib39]) and neuronal differentiation ([@bib22]). Hepatic-like cells showed characteristic morphology, stained positive for lineage-specific markers such as α-fetoprotein (AFP), HNF4-α (HNF4a) and human albumin (ALB), and expressed lineage-specific genes ([Figures 1](#fig1){ref-type="fig"}A, [S1](#app3){ref-type="sec"}I, and S1J). Neurons expressed specific markers such as class III β-tubulin (TUJ1) and microtubule-associated protein 2 (MAP2) ([Figure 1](#fig1){ref-type="fig"}B). Cell viability was significantly reduced in NPC1 iPSC-derived hepatic-like cells and aged neuronal cultures as compared to control iPSC and hESC-derived cells ([Figures 1](#fig1){ref-type="fig"}C and 1D).

Generation of Isogenic Mutant and Control NPC1 iPSCs {#sec2.2}
----------------------------------------------------

Recent progress in human gene targeting using zinc finger nuclease and TALENs allows for the correction of a single disease-causing point mutation in iPSCs, and thereby the generation of isogenic disease and control cell lines ([@bib44; @bib51]). To repair the *NPC1*^*I1061T*^ mutation, we designed TALEN pairs introducing a DNA double-strand break close to nt 3181C ([Figures 2](#fig2){ref-type="fig"}A, 2B, and [S2](#app3){ref-type="sec"}A; see [Supplemental Information](#app3){ref-type="sec"}) ([@bib4]). The donor construct contained a puromycin selection cassette (puroΔtk) flanked by piggyBac terminal repeats ([@bib51]) ([Figure 2](#fig2){ref-type="fig"}B) allowing for correction of the *I1061T* mutation and the complete removal of the selection cassette. We targeted a NPC patient line that is compound heterozygous and carries the *NPC1*^*I1061T*^ mutation on one allele (NPC1-2) ([Table 1](#tbl1){ref-type="table"}). Integration of the piggyBac cassette was confirmed by Southern blot analysis and PCR ([Figure S2](#app3){ref-type="sec"}B; data not shown). Out of 146 NPC1-2 iPSC-derived clones analyzed, five were targeted on the allele carrying the *I1061T* mutation ([Table S1](#app3){ref-type="sec"}). In addition, we targeted the control line (control-2) that has one *NPC1* mutant and one wild-type allele ([Table 1](#tbl1){ref-type="table"}). Two clones had the selection cassette integrated on the wild-type allele ([Table S1](#app3){ref-type="sec"}). Integration of the piggyBac cassette on the wild-type allele in this cell line disrupted exon 21 and thereby generated a second mutant allele (Control-2-Mut). Overall, we observed a targeting efficiency of 6%. Transient expression of transposase in the targeted clones led to removal of the piggyBac selection cassette, which was confirmed by Southern blot ([Figure 2](#fig2){ref-type="fig"}C). We did not detect any reintegration of the piggyBac element ([Figure S2](#app3){ref-type="sec"}C). Correction of the *I1061T* mutation in the NPC1-2-Corr line and restoration of the wild-type allele in the Control-2-Corr line were further confirmed by sequence analysis and PCR ([Figures 2](#fig2){ref-type="fig"}D and [S2](#app3){ref-type="sec"}D). Analysis of the genomic DNA of corrected clones at the top ten predicted off-target cutting loci of TALEN pair 1 revealed no mutations (see [Supplemental Information](#app3){ref-type="sec"}; data not shown). Genome-wide comparison of copy number variations (CNVs) of independent NPC1 iPSC lines and the isogenic pairs using Illumina sequencing showed no major changes ([Figures S2](#app3){ref-type="sec"}E and S2F). Corrected NPC1 iPSC lines expressed pluripotency markers, were capable of forming teratomas and efficiently differentiated into hepatic-like and neuronal cells ([Figures 2](#fig2){ref-type="fig"}E, [S2](#app3){ref-type="sec"}G, and S2H). Loss and restoration of NPC1 protein levels in the targeted NPC1 iPSCs was confirmed by western blot analysis ([Figure 2](#fig2){ref-type="fig"}F).

NPC1 iPSC-Derived Hepatic and Neuronal Cells Show Defects in Cholesterol Metabolism {#sec2.3}
-----------------------------------------------------------------------------------

NPC disease is considered to be primarily a neurodegenerative disorder; nevertheless, hepatomegaly is one of the first detectable disease manifestations in more than 50% of NPC patients, and a significant number of infants die from liver failure ([@bib21; @bib33; @bib48]), but NPC1 deficiency in human disease-affected cell types has not been analyzed because of a lack of availability. We detected cholesterol accumulation in the LE/L compartments by Filipin staining in NPC1-deficient hepatic-like and neuronal cells ([Figures 3](#fig3){ref-type="fig"}A and 3B) similar to that observed in NPC1 iPSC-derived fibroblasts ([Figures S3](#app3){ref-type="sec"}A and S3B). Sequestration of cholesterol in the LE/L compartments consequently affects downstream pathways, such as cholesterol ester (CE) synthesis ([@bib1; @bib2; @bib9]), prompting us to analyze cholesterol esterification and the cholesterol sensing machinery in mutant hepatic cells. Defects in acetyl-CoA acetyltransferase-mediated synthesis of CE were detected by measuring the incorporation of \[^14^C\]oleate ([@bib2; @bib9]). Cholesteryl \[^14^C\]oleate synthesis was markedly increased in control hepatic-like cells after LDL treatment, whereas no increase was detected in NPC1-deficient hepatic-like cells ([Figure 3](#fig3){ref-type="fig"}C), suggesting an impairment in CE synthesis. Hydroxypropyl-β-cyclodextrin (HP-β-cyclodextrin), which releases cholesterol from the LE/L compartments ([@bib1]), allowed CE synthesis in NPC1-deficient hepatic-like cells but not in the control cells ([Figure 3](#fig3){ref-type="fig"}D). HP-β-cyclodextrin (0.2%) was sufficient to induce maximal formation of cholesteryl \[^14^C\]oleate in NPC1-deficient hepatic-like cells. We did not detect any general effect on triglyceride formation in the treated hepatic cells ([Figure S3](#app3){ref-type="sec"}C). NPC1-deficient and control cells treated with 25-hydroxycholesterol (25-HC), which stimulates cholesterol esterification by causing cholesterol to translocate directly from the plasma membrane to the ER, responded in a similar range ([Figure S3](#app3){ref-type="sec"}D) ([@bib1]), indicating that components of the cholesterol pathway downstream of LE/L compartments were intact. Our data show that sequestration of LE/L-resident cholesterol impairs cholesterol esterification in NPC1-deficient hepatic-like cells.

Rescue of Cholesterol Defects by Treatment with HP-β-Cyclodextrin or by Genetic Correction of the *NPC1*^*I1061T*^ Mutation {#sec2.4}
---------------------------------------------------------------------------------------------------------------------------

A block in cholesterol transport to the ER impairs transcriptional regulation caused by constant activation of proteolytic cleavage of the sterol regulatory element-binding proteins (SREBPs) ([@bib14]). Because cleaved SREBP translocates to the nucleus and activates transcription, we analyzed the formation of nuclear SREBP-2 (nSREBP-2) in NPC1-deficient hepatic cells. Although in control cells nSREBP-2 was decreased in the nuclear fraction in response to treatment with 10% serum, we did not detect any changes in NPC1-deficient cells ([Figure 3](#fig3){ref-type="fig"}E). Similar observations were made in NPC1 iPSC-derived neurons after treatment with 2% serum ([Figure 3](#fig3){ref-type="fig"}F). In addition, increased nSREBP-2 levels in NPC1-deficient hepatic cells lead to upregulation of transcription of specific target genes, such as SREBPs themselves. We detected an increase in SREBP RNA levels in NPC1-deficient hepatic cells after treatment with 10% serum, whereas RNA levels in controls were downregulated ([Figure S3](#app3){ref-type="sec"}E). Upon combined treatment with 10% serum and 0.2% HP-β-cyclodextrin, transcript levels of SREBP and low-density lipoprotein receptor (LDL-R) decreased in NPC1-deficient hepatic cultures and were comparable to those in control cells after treatment with 10% serum only ([Figures S3](#app3){ref-type="sec"}F and S3G). After correction of the *NPC1*^*I1061T*^ mutation, NPC iPSC-derived hepatic and neuronal cells showed normal cholesterol distribution ([Figures 3](#fig3){ref-type="fig"}A and 3B) and responded to serum treatment by suppressing SREBP2 cleavage, as evident by a reduction in nSREBP2 protein and SREBP transcript levels ([Figures 3](#fig3){ref-type="fig"}E, 3F, and [S3](#app3){ref-type="sec"}E). These results confirmed defects in cholesterol sensing in NPC1 iPSC-derived hepatic and neuronal cells that could be rescued by genetic correction of *NPC1* ^*I1061T*^.

Impairment of Autophagic Flux in NPC1 iPSC-Derived Human Disease-Affected Cell Types {#sec2.5}
------------------------------------------------------------------------------------

Emerging evidence indicates that impaired autophagy contributes to neurodegenerative and liver disorders ([@bib12; @bib16; @bib26; @bib32]) and is thought to be involved in NPC1 disease ([@bib6; @bib28; @bib38]). We assessed perturbation in autophagic flux in NPC1-deficient hepatic and neuronal cells. To monitor autophagic flux in NPC patient-specific iPSC-derived cells, we measured the levels of the specific autophagosome maker LC3-II (light chain 3 of microtubule-associated protein 1) and the pathway-specific substrate, p62. Levels of LC3-II directly correlate with the steady-state number of autophagosomes, whereas the levels of p62 reflect autophagic turnover ([@bib15; @bib52]). Both LC3-II and p62 levels were significantly increased in NPC1-deficient hepatic-like cells compared to the control cells ([Figure 4](#fig4){ref-type="fig"}A), suggesting impaired autophagic flux. However, p62 transcript levels in control and NPC1-deficient hepatic cells were comparable ([Figure S4](#app3){ref-type="sec"}A), implying that accumulation of p62 protein is due to reduced clearance rather than diminished transcription. Similar observations were made in NPC1 iPSC-derived neuronal cultures ([Figure 4](#fig4){ref-type="fig"}B). We further analyzed autophagosome synthesis with a saturating concentration of bafilomycin A~1~ (BafA~1~), which inhibits lysosomal acidification and prevents LC3-II degradation, thus causing its accumulation ([@bib15]). After BafA~1~ treatment, the accumulation of LC3-II in NPC1-deficient hepatic-like and neuronal cells was abrogated compared to controls ([Figures 4](#fig4){ref-type="fig"}C and 4D). These data suggest that accumulation of autophagosomes is not due to increased autophagosome synthesis but rather occurs because of a block in autophagic flux in NPC1-deficient cells. We did not find alterations in the upstream events regulating autophagosome synthesis, such as the levels of Beclin 1 and Atg5-Atg12 conjugation, in NPC1-deficient cells ([Figures S4](#app3){ref-type="sec"}B and S4C). These data are consistent with our recent findings related to a block in autophagic flux seen in mouse NPC1 mutant cells that is attributed to impaired formation of amphisomes, resulting from defects in the SNARE machinery that regulates autophagosome maturation ([@bib38]). Impaired SNARE functioning and autophagic flux are also reported in other lysosomal storage disorders, such as multiple sulphatase deficiency and mucopolysaccharidosis type IIIA, where LE/L-resident cholesterol accumulation is observed ([@bib7]). We were not able to detect impaired autophagy in NPC1-deficient iPSCs, hepatic and neuronal progenitor cells, or early neurons (data not shown). Our data argue against previous findings that attributed the increase in steady-state LC3-II levels in human cells to an induction of autophagy ([@bib28; @bib30]).

Defect in Autophagy Is Directly Linked to the *NPC1*^*I1061T*^ Mutation {#sec2.6}
-----------------------------------------------------------------------

To assess whether the defect in autophagic flux is caused by NPC1 deficiency, we compared LC3-II and p62 levels in hepatic and neuronal cells carrying the *NPC1*^*I1061T*^ mutation and their isogenic control. We found that basal autophagy was restored in the mutant cells after genetic correction ([Figures 4](#fig4){ref-type="fig"}E and 4F). In contrast, disruption of the *NPC1* wild-type allele in control hepatic cells, which led to loss of NPC1 expression ([Figure 2](#fig2){ref-type="fig"}F), resulted in marked increase of LC3-II and p62 levels, which phenocopied the effects found in NPC1 iPSC-derived hepatic cells ([Figure S4](#app3){ref-type="sec"}D). Electron microscopic analysis confirmed accumulation of autophagic vacuoles and lipid droplets (LDs) in NPC1 mutant hepatic cells, a phenotype that was abolished after correction of the *NPC1*^*I1061T*^ mutation ([Figures 4](#fig4){ref-type="fig"}G and [S4](#app3){ref-type="sec"}E). Thus, genetic correction of the *NPC1* mutation rescued both the cholesterol and autophagy abnormalities.

Treatment with HP-β-cyclodextrin ([@bib47]) did not rescue the perturbation in autophagic flux. Instead, we observed an increased block in autophagy, which was dose dependent as evident by elevation of LC3-II and p62 levels ([Figure S5](#app3){ref-type="sec"}A). A lower dose of HP-β-cyclodextrin (0.2%), sufficient to restore defects in cholesterol metabolism as shown by induction of cholesterol esterification ([Figure 3](#fig3){ref-type="fig"}D), did not further impair autophagy in NPC1 iPSC-derived hepatic-like cells ([Figure S5](#app3){ref-type="sec"}A). In summary, we show a block in autophagic flux in NPC1 disease-affected human cells. This defect was abrogated in hepatic-like and neuronal cells by genetic correction of the *NPC1*^*I1061T*^ mutation but not by depleting cholesterol, thus implying that impaired autophagy is directly linked to loss of NPC1 protein function.

Induction of Autophagy Rescues the Defect in Basal Autophagy and Increases Cell Viability in NPC1-Deficient Hepatic-like and Neuronal Cells {#sec2.7}
-------------------------------------------------------------------------------------------------------------------------------------------

Upregulation of autophagy is beneficial in transgenic models of several neurodegenerative and certain liver disorders ([@bib34; @bib36]). Using NPC iPSC-derived cells may allow the identification of potent compounds that can rescue the autophagy defects in human disease-affected cells. We found that induction of autophagy by inhibiting the mammalian target of rapamycin (mTOR) pathway with rapamycin (Rap) or starvation ([@bib32]) significantly reduced p62 levels in NPC1 iPSC-derived hepatic cells to amounts comparable to the basal levels in control cells ([Figures 5](#fig5){ref-type="fig"}A and [S5](#app3){ref-type="sec"}B). Because long-term treatment with mTOR inhibitors may have unfavorable side effects due to critical functions of mTOR in growth and translation ([@bib36]), we performed a small-scale candidate drug screen testing different concentrations of mTOR-independent autophagy enhancers, such as carbamazepine (CBZ), verapamil (Ver), trehalose (Tre), and SMER28 ([Figures 5](#fig5){ref-type="fig"}B and [S5](#app3){ref-type="sec"}C; see [Supplemental Information](#app3){ref-type="sec"}). These compounds are reported to be protective in *Drosophila* or mouse models of Alzheimer's, Parkinson's, and Huntington's disease ([@bib34; @bib36]) or α-antitrypsin deficiency ([@bib13; @bib36]). By measuring p62 clearance, we found CBZ to be the most potent drug in rescuing the defective autophagy phenotype in NPC1 iPSC-derived hepatic cells ([Figure 5](#fig5){ref-type="fig"}B). CBZ, which induces mTOR-independent autophagy by lowering inositol and IP~3~ levels ([@bib37]), reduced p62 levels to a similar extent as observed with rapamycin treatment ([Figure 5](#fig5){ref-type="fig"}B). Our data suggest that CBZ-mediated restoration of autophagic flux was sufficient to overcome the block observed in NPC1-deficient hepatic cells, which may be due to a recently characterized bypass mechanism ([@bib38]).

We assessed the possibility of using CBZ in combination with HP-β-cyclodextrin (0.2%, sufficient to induce cholesterol ester formation without perturbing autophagy; [Figures 3](#fig3){ref-type="fig"}D and [S5](#app3){ref-type="sec"}A) to simultaneously restore both the cholesterol and autophagy defects. We found a significant reduction in p62 levels after dual treatment comparable to the effects of CBZ alone ([Figure 5](#fig5){ref-type="fig"}C), as well as a partial rescue of the defective cholesterol metabolism as observed by downregulation of SREBP protein, and SREBP and LDL-R transcript levels ([Figures S5](#app3){ref-type="sec"}D and S5E). p62 transcript levels were not affected by the compound treatment ([Figure S5](#app3){ref-type="sec"}F), suggesting that the clearance of p62 protein levels is due to increased autophagic degradation. Chemical induction of autophagy with Rap or CBZ, or CBZ in combination with a low dose of HP-β-cyclodextrin, significantly increased cell viability of NPC1-deficient hepatic cells ([Figures 5](#fig5){ref-type="fig"}D and 5E).

We further evaluated the effects of autophagy-inducing compounds using NPC1 iPSC-derived neuronal cultures. In addition to Rap and CBZ, Tre and Ver significantly rescued the defective autophagy phenotype in these cells, as assessed by p62 clearance ([Figures 5](#fig5){ref-type="fig"}F and [S5](#app3){ref-type="sec"}G). Notably, cell viability in NPC1-deficient neuronal cultures was significantly increased with all the chemical inducers of autophagy alone, as well as in combination with 0.2% HP-β-cyclodextrin ([Figure 5](#fig5){ref-type="fig"}G). Although our data suggest that induction of autophagy by itself is cytoprotective in the context of NPC disease, combining this treatment with a partial release of the LE/L-resident cholesterol can restore the autophagy defects as well as improve cholesterol homeostasis in the liver and the brain.

Discussion {#sec3}
==========

In summary, our data show that patient-specific NPC1 iPSC-derived hepatic and neuronal cells are less viable and develop disease-relevant defects, such as in cholesterol metabolism and autophagic flux ([Figure 6](#fig6){ref-type="fig"}). In contrast to previous reports, we do not observe similar defects in NPC1 iPSCs or in neuronal and liver progenitor cells ([@bib46]). Both these defects are abrogated after correction of the *NPC1*^*I1061T*^ mutation, implying that the NPC1 protein has a functional role in both the processes. Recent studies provide evidence that regulation of lipolysis and autophagy are interrelated and controlled by similar regulatory mechanisms ([@bib40]). We speculate that disturbance of this interrelation may trap NPC1-deficient cells in a vicious cycle where inhibition of autophagy will cause increased intracellular lipid content ([@bib29; @bib38; @bib40; @bib41]), a condition that may further deteriorate by the release of high levels of cholesterol ([@bib31]) or by blocking autophagy ([@bib23; @bib38]). Brain and liver-specific deletion of essential autophagy genes (such as *Atg5* or *Atg7*) in normal mice causes neurodegeneration and liver injury, respectively ([@bib12; @bib17; @bib18]), similar to those observed in NPC1 patients. These observations further support our assumption that impairment in autophagy is a crucial contributing factor for NPC disease.

Our data argue that induction of autophagy might be a plausible treatment option for NPC disease. Such a strategy is supported by our recent study in NPC1 mutant mouse cells showing that a block in autophagic flux due to defects in amphisome formation can be bypassed by stimulating autophagy ([@bib38]). Induction of autophagy has been shown to be protective in several models of neurodegenerative and liver diseases ([@bib13; @bib32; @bib34; @bib36]). Because mTOR governs critical cellular function such as translation and cell growth, small molecule autophagy enhancers acting independently of mTOR might be more suitable for long-term treatment of patients. Screening mTOR-independent autophagy inducers that are known to increase autophagic flux in various in vitro and in vivo transgenic disease models ([@bib36]) revealed cell type specificity, because only CBZ could overcome the impairment in autophagy in both NPC1 iPSC-derived hepatic and neuronal cells. These findings underline the unique value of using human iPSC-derived disease-relevant cells for identifying potent compounds of biomedical relevance ([@bib10]). We show that higher concentrations of HP-β-cyclodextrin treatment further perturb autophagic flux in NPC1 iPSC-derived hepatic cells with likely deleterious cellular consequences. These observations are consistent with earlier findings describing neurotoxic effects of HP-β-cyclodextrin treatment in neurons from NPC1 mutant mice ([@bib31]).

Our data indicate that induction of autophagy itself is beneficial, and in combination with a cholesterol-depleting agent (such as low dose of HP-β-cyclodextrin) that does not impact on autophagy will rescue both the autophagy and cholesterol defects in NPC1 patients. Our study suggests that inducing autophagy with CBZ may have overall benefit for the treatment of NPC disease as it might be effective in liver and brain.

Experimental Procedures {#sec4}
=======================

HiPSC Derivation, Cultivation, and Differentiation {#sec4.1}
--------------------------------------------------

Transgene-free iPSCs were generated from fibroblasts of NPC patients ([Table 1](#tbl1){ref-type="table"}) using Cre-excisable lentiviruses encoding a polycistronic doxcycycline-inducible (DOX) expression cassette containing all four reprogramming factors Oct4, Klf4, Sox2, c-Myc (OKSM) (pHAGE2-TetOminiCMV-hSTEMCCA-loxP) ([@bib45]) and a modified tetracycline-controlled trans-activator (FUW-M2rtTA-loxP) ([@bib43]). All pluripotent cell lines have been characterized using standard pluripotency assays (see [Supplemental Experimental Procedures](#app3){ref-type="sec"}). All protocols were approved by the relevant Institutional Review Board (Massachusetts Institute of Technology) and the Embryonic Stem Cell Research Oversight Committees (Whitehead Institute). Differentiation of iPSCs into hepatic-like cells was induced after single-cell replating of iPSCs on matrigel following published protocols ([@bib39]). Neuronal progenitors (NPs) and neurons were derived using an embryoid body (EB)-based protocol ([@bib22]).

TALEN and Donor Design and Generation {#sec4.2}
-------------------------------------

TALENs were designed according to previously published principles ([@bib4; @bib25]). All TALENs used the +63 truncation point for fusion to the obligate heterodimeric FokI cleavage domain ([@bib5; @bib25]). The tandem arrays of TALE repeats were assembled as described previously ([@bib22]) (see [Supplemental Information](#app3){ref-type="sec"}). Their editing activity was assayed using the Surveyor nuclease (Transgenomic) ([@bib11]). The targeted loci were PCR amplified using the following primer pairs: Cel-I-NPC1-F (5′-atgctgcctatagttctgcag-3′) and Cel-I-NPC1-R (5′-tcacagagactttagattctg-3′) for the *NPC1* locus. PCR products were then denatured, rehybridized, digested with the Surveyor nuclease, and analyzed. *NPC1*^*I1061T*^-specific TALENS pairs introducing a DNA double-strand break in exon 21 (nt 3181C) were designed according to previously published principles ([@bib4]). To increase targeting efficiency, we used a donor construct containing a puromycin selection cassette (PGK-puroΔtk-pGH-pA cassette) flanked by piggyBac terminal repeats ([@bib51]). The 700 bp 3′ homology arm introduced the ACA (Thr) to ATA (Ile) switch correcting for the mutation. In addition, a silent CTT to TTA (Leu) codon switch 3 bp upstream of the mutation was introduced, generating the TTAA sequence necessary for the piggyBac excision ([Figures 2](#fig2){ref-type="fig"}A and 2B).

TALEN-Mediated Gene Targeting and Transposon Excision {#sec4.3}
-----------------------------------------------------

Cells were prepared as described previously ([@bib19; @bib43]). Cells (1 × 10^7^) were electroporated with 35 μg of donor plasmid (designed and assembled by H.W.) and 7.5 μg of each TALEN expression vector (Gene Pulser Xcell System, Bio-Rad: 250 V, 500 μF, 0.4 cm cuvettes) and subsequently plated on DR4 MEF feeder layers in hESC medium supplemented with ROCK inhibitor for the first 24 hr. Puromycin selection (0.5 μg/ml) was started 72 hr after electroporation. Individual colonies were picked 10--14 days after electroporation. Correctly targeted clones were confirmed by Southern blot (AseI, EcoRI digested) and used for transposon removal. Cells (1 × 10^7^) were electroporated with 10 μg of hyperactive *piggyBac* transposase expression vector (pCMV-hypBase) as described previously ([@bib43]). On day 4, medium was changed to hESC medium containing 0.25 μM FIAU. Individual colonies were picked and expanded. Genotype and deletion of the piggyBac transposon were analyzed by Southern blot (AseI, EcoRI digest). Additionally PCR and sequencing mutation analysis was performed. Genomic DNA was amplified with primers NPC1-Wt-F (5′-cctttgattatacatgaaaccag-3′), NPC1-I1061T-Mut-F (5′-gaagaaagcccgacttac-3′), NPC1-I1061T-Corr-F (5′-gaagaaagcccgattaat-3′), respectively, and NPC1-R (5′-gagcattccacagcattctg-3′) under standard PCR conditions. PCR products were sequenced (Applied Biosystems Model 3730 capillary DNA sequencer with Big Dye Terminator Cycle Sequencing Kit).

Prediction of NPC1 TALENs Off-Target Sites {#sec4.4}
------------------------------------------

The position weight matrices (PWMs) of NPC1 TALEN pairs (see [Supplemental Information](#app3){ref-type="sec"}) were constructed using model 3 as described previously ([@bib27]) (see [Supplemental Information](#app3){ref-type="sec"}).

Immunostaining {#sec4.5}
--------------

Immunostaining was performed according to standard protocols using primary antibodies listed in the [Supplemental Information](#app3){ref-type="sec"}. Cholesterol was detected by Filipin staining (50 μg/ml Filipin complex, *Streptomyces filipinensis*; Sigma-Aldrich).

Acyl-CoA Acetyltransferase Assay {#sec4.6}
--------------------------------

Defects in cholesterol metabolism were assessed using the Acyl-CoA Acetyltransferase Assay. The rate of incorporation of \[^14^C\]oleate into cholesterol \[^14^C\]oleate and \[^14^C\]triglycerides by intact cell monolayers was measured as previously described ([@bib9]).

Immunoblot Analysis {#sec4.7}
-------------------

Cell pellets were lysed on ice in Lysis Buffer (10 mM Tris-HCl \[pH 7.4\], 2% SDS, 1 mM DTT, 10% glycerol, and 120 mg/ml urea) for 30 min in presence of Complete EDTA-free Protease Inhibitor Cocktail (Roche Diagnostics) and subjected to SDS-PAGE and standard immunoblot analysis. Primary antibodies used are listed in the [Supplemental Information](#app3){ref-type="sec"}. Amersham ECL Western Blotting Detection Reagent (GE Healthcare) was used for visualization.

Chemical Compounds {#sec4.8}
------------------

Autophagic flux in NPC1 iPSC-derived cells was assessed using a saturating concentration of bafilomycin A~1~ (BafA~1~) clamping LC3-II/autophagosome degradation ([@bib15]). To test the possibility of inducing autophagy, we performed a candidate drug screen including described mTOR-independent autophagy inducers ([@bib36]) ([Figure S5](#app3){ref-type="sec"}G; [Supplemental Information](#app3){ref-type="sec"}). Their effect was analyzed by measuring p62 levels and cell viability by FITC-Annexin V/ PI staining. Compounds used for treatment of hepatic-like cells were bafilomycin A1 (Enzo Life Sciences), rapamycin (LC Laboratories), carbamazepine, verapamil, trehalose, SMER28, and HP-β-cyclodextrin (all Sigma-Aldrich). Cells were treated with compounds as indicated.

Statistical Analyses {#sec4.9}
--------------------

Densitometry analyses on the immunoblots were done by ImageJ software (NIH) by measuring levels of the protein of interest relative to the loading control, as previously described ([@bib49]). The control condition was set to 100%, and the data were represented as mean ± SEM. The y axis values are shown in percentages (%). Experiments were performed in triplicates at least twice. The p values for densitometry analyses, vesicle number, and aggregate formation were determined by Student's t test (unpaired) using Prism 6 software (GraphPad), as previously described ([@bib20]). ^∗∗∗^p \< 0.001; ^∗∗^p \< 0.01; ^∗^p \< 0.05; ns, nonsignificant.
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====================
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![Generation and Characterization of Patient-Specific NPC1 iPSCs\
(A) Immunofluorescence staining of hepatic cultures derived from representative NPC1 iPSC lines 21 days after induction of hepatocyte differentiation for Alpha-fetoprotein (AFP; green) and HNF4a (red). Nuclei were stained with DAPI (blue). Scale bar, 100 μm.\
(B) Immunofluorescence staining of neuronal cultures derived from representative NPC1 iPSC lines 14 days after induction of differentiation for neuron-specific microtubule-associated protein 2 (MAP2; green) and class III β-tubulin (TUJI; red). Nuclei were stained with DAPI (blue). Scale bar, 100 μm.\
(C) FACS analysis of cell viability and apoptosis in control and NPC1 iPSC-derived hepatic cultures measuring FITC-Annexin V and propidium iodide staining. Graphical data (right panel) represent mean ± SE (n = 3).\
(D) Analysis of cell death in control and NPC1 iPSC-derived 5-week-old TUJI positive neurons. Nuclei stained with DAPI. Arrow shows apoptotic nuclei. Scale bar, 10 μm. Graphical data represent mean ± SE (n = 3).\
Results shown are representative of at least three independent experiments using two different clones of each line unless otherwise indicated. ^∗∗∗^p \< 0.001; ^∗∗^p \< 0.01; ^∗^p \< 0.05; ns, nonsignificant.](gr1){#fig1}

![Correction of NPC1^*I1061T*^ Mutation in Patient-Specific iPSCs\
(A) Schematic overview of specific TALENs cutting site in the *NPC1* gene. Blue letters are indicating the wild-type base and amino acid, respectively; red indicates the mutation.\
(B) Schematic overview depicting the *NPC1*^*I1061T*^ targeting strategy showing piggyBac (PB) donor plasmid design with homologous 5′- and 3′-arms, PB terminal repeats (PB-TR), and selection cassette (PGK-puroTK, pGH-pA). Exons (white boxes), restriction sites, and location of external 5′ and 3′ Southern blot probes (red bars) are indicted. Enlarged sequence indicates *I1061T* mutation in exon 21 (red base). Introduced changes are labeled in green.\
(C) Southern blot analysis of NPC1 iPSCs after excision of PB selection cassette. Fragment sizes of wild-type (wt), corrected (Corr.), and targeted alleles are indicated. Excised clones are marked with an asterisk.\
(D) Sequencing of genomic *NPC1* locus in indicated NPC1 iPSC lines. The corrected *I1061T* mutation is marked with an arrow, induced bp changes with an asterisk.\
(E) Immunofluorescence staining of hepatic \[AFP (green) and HNF4a (red)\] and neuronal cultures \[MAP2 (green) and TUJ1 (red or green, respectively)\] derived from representative NPC1-2-Corr\#36 line. Nuclei were stained with DAPI (blue). Scale bar, 100 μm and 10 μm (lower right).\
(F) Immunoblot analysis of indicated control and NPC1 iPSCs lines detecting NPC1 and actin protein levels.\
Results shown in (C)--(F) are representative of at least three independent experiments using two different clones of each line.](gr2){#fig2}

![Analysis of Cholesterol Metabolism in Isogenic NPC1 iPSC-Derived Cell Types\
(A and B) Immunofluorescence staining of representative control, mutant, and corrected NPC1 iPSC-derived hepatic (A) and neuronal (B) cells with lineage markers \[AFP, green; HNF4a, red (A); TUJI, green (B)\], respectively. Endogenous cholesterol was detected by Filipin staining (white) in the same samples as the lineage marker staining (A) or in duplicate samples of the same experiment (B). Scale bar, (A) 100 μm and (B) 10 μm. Results shown are representative of at least three independent experiments using two different clones of each line.\
(C) Cholesterol ester formation in NPC1-deficient and control hepatic-like cultures after exposure to different concentrations of low-density lipoprotein (LDL). Mean variation for each of the duplicate incubations for control, NPC1-1, and NPC1-2 were in a range between 9% and 20% for the untreated samples and between 1%--31% for the data points at the different LDL concentrations, respectively.\
(D) Cholesterol ester formation in NPC1 iPSC-derived hepatic cultures after exposure to different concentrations of HP-β-cyclodextrin (HP-β-CD \[%w/v\]). Mean variations for each of the duplicate incubations for control, NPC1-1, and NPC1-2 were in a range between 1% and 37% for the untreated samples and between 0.2% and 24% for the data points at the different HP-β-CD concentrations, respectively.\
(C and D) Results shown are the mean of duplicates of each cell line and representative for three independent experiments using different clones of indicated cell lines.\
(E and F) Immunoblot analysis detecting the activation of sterol regulatory element-binding protein 2 (SREBP2) cleavage in NPC1 iPSC-derived hepatic (E) and neuronal (F) cells after incubation with indicated serum concentrations. pSREBP2 (precursor SREBP2) in the cytoplasmic and nSREBP2 in the nuclear fraction of cell lysates were detected. Protein sizes are indicated. Results shown are representative of at least three independent experiments using two different clones of each line.](gr3){#fig3}

![Genetic Correction of Autophagy Phenotype in NPC1 iPSC-Derived cells\
(A and B) Immunoblot analysis and quantifications of p62 and LC3-II levels using anti-p62, anti-LC3, and anti-GAPDH antibodies in hepatic (A) and neuronal cultures (B) derived from indicated control and NPC1 iPSC lines. Graphical data represent mean ± SE (n = 4).\
(C and D) Immunoblot analysis and quantification of LC3-II levels using anti-LC3 and anti-GAPDH antibodies in hepatic (C) and neuronal cultures (D) derived from control and NPC1 iPSC lines, treated with or without 400 nM bafilomycin A~1~ (BafA~1~) for 4 hr. Graphical data represent mean ± SE (n = 3).\
(E and F) Immunoblot analysis and quantifications of p62 and LC3-II levels in hepatic (E) and neuronal cultures (F) derived from the NPC1-2 iPSC line after correction of the *NPC1*^*I1061T*^ mutation. Graphical data represent mean ± SE (n = 3).\
(G) Electron microscopy images of representative NPC1 iPSC-derived hepatic-like cells before and after genome editing. Arrows are indicating autophagic vacuoles. Graphical data represent mean ± SE (n = 3). Nucleus (N), rough endoplasmatic reticulum (rER), mitochondria (M), Golgi (G). Scale bar, 500 nm.\
Results shown are representative for at least three independent experiments using two different clones of each line. ^∗∗∗^p \< 0.001; ^∗∗^p \< 0.01; ^∗^p \< 0.05; ns, nonsignificant.](gr4){#fig4}

![Chemical Correction of Autophagy Phenotype in NPC1 iPSC-Derived cells\
(A) Immunoblot analysis and quantification of p62 levels using anti-p62 and anti-GAPDH antibodies in control and NPC1 iPSC-derived hepatic cultures, treated with either DMSO (vehicle control) or rapamycin (Rap). Graphical data represent mean ± SE (n = 3).\
(B) Immunoblot analysis and quantification of p62 levels using anti-p62 and anti-GAPDH antibodies in control and NPC1 iPSC-derived hepatic cultures after treatment with autophagy inducing compounds: untreated (UT), rapamycin (Rap), carbamazepine (CBZ), verapamil (Ver), trehelose (Tre), and SMER28. Graphical data represent mean ± SE (n = 3).\
(C) Immunoblot analysis and quantification of p62 levels using anti-p62 and anti-GAPDH antibodies in NPC1 iPSC-derived hepatic cultures, treated with CBZ and HP-β-CD as indicated. Graphical data represent mean ± SE (n = 3).\
(D and E) FACS analysis of cell viability and apoptosis in NPC1 iPSC-derived hepatic cultures after treatment with indicated compounds measuring FITC-Annexin V and propidium iodide staining. (E) Graphical data represent mean ± SE (n = 3).\
(F) Immunoblot analysis and quantification of p62 levels using anti-p62 and anti-GAPDH antibodies in NPC1 iPSC-derived neuronal cultures after treatment with autophagy inducing compounds: untreated (UT), Rap, CBZ, Ver, and Tre. Graphical data represent mean ± SE (n = 3).\
(G) Analysis of cell death in NPC1 iPSC-derived 5-week-old neurons by assessing fragmented and TUNNEL positive nuclei. Graphical data represent mean ± SE (n = 6).\
Results shown are representative for at least two independent experiments using two different clones of each line. ^∗∗∗^p \< 0.001; ^∗∗^p \< 0.01; ^∗^p \< 0.05; ns, nonsignificant.](gr5){#fig5}

![Schematic Overview of Correction of Functional Defects in NPC Disease-Affected Cell Types\
Left panel shows cholesterol distribution and autophagic flux under normal conditions. Middle panel shows the effects due to loss of NPC1 protein function on cholesterol metabolism and autophagic flux. Mutations in the *NPC1* gene on both alleles lead to accumulation of cholesterol in the LE/L compartments by inhibiting its efflux, and to a block in autophagic flux causing accumulation of autophagosomes and autophagy substrate arising due to impaired formation of amphisomes. Chemical correction of disease related phenotypes are achieved by HP-β-cyclodextrin-mediated cholesterol release and CBZ-mediated autophagy induction (green arrows, right panel). Restoration of autophagic flux by autophagy inducer is possibly through a bypass mechanism.](gr6){#fig6}

###### 

Overview of Generated NPC Patient-Specific iPS Cell Lines and Used ESCs

  iPS/ES Clone ID          Parental Cell Line   Donor                                                      Age of Biopsy (years)   Reprogramming Factors             Number of Factor-free iPS Clones   Number of iPS Clones Characterized   Cell Line Designation
  ------------------------ -------------------- ---------------------------------------------------------- ----------------------- --------------------------------- ---------------------------------- ------------------------------------ ----------------------------------------
  NPC1-1 (\#4, \#13)       GM18453              Niemann-Pick disease, type C NPC1 (I1061T/I1061T)          nk                      loxP-TetO-OKSM, loxP-FUW-M2rtTA   13                                 2                                    WIBR-IPS-NPC1^I1061T/\ I1061T^
  NPC1-2 (\#9, \#26)       GM03123              Niemann-Pick disease, type C NPC1 (P237S/I1061T)           9                       loxP-TetO-OKSM, loxP-FUW-M2rtTA   15                                 2                                    WIBR-IPS-NPC1^P237S/\ I1061T^
  NPC1-3 (\#4, \#47)       GM22870              Niemann-Pick disease, type C NPC1 (1920 delG/1009G \> A)   4                       loxP-TetO-OKSM, loxP-FUW-M2rtTA   15                                 2                                    WIBR-IPS-NPC1^1920\ delG/1009G\ \>\ A^
  NPC1-4 (\#17, \#20)      GM22871              Niemann-Pick disease, type C NPC1 (1920 delG/1009G \> A)   4                       loxP-TetO-OKSM, loxP-FUW-M2rtTA   9                                  2                                    WIBR-IPS-NPC1^1920\ delG/1009G\ \>\ A^
  Control-1                hES Cell Line                                                                                                                                                                                                     WIBR3
  Control-2 (\#11, \#13)   GM23151              Niemann-Pick disease, type C NPC1 (1920 delG/wt)           39                      loxP-TetO-OKSM, loxP-FUW-M2rtTA   10                                 2                                    WIBR-IPS-NPC1^1920\ delG/wt^

nk, not known.

[^1]: Co-first author
